---
document_datetime: 2024-07-24 12:18:25
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/duoresp-spiromax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: duoresp-spiromax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 8.5548117
conversion_datetime: 2025-12-26 20:34:10.577116
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## DuoResp Spiromax

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IG/1765              | A.7 - Administrative change - Deletion of manufacturing sites                                                               | 18/07/2024                          |                                             | Annex II and PL                  |           |
| IA/0043              | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier | 19/04/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0042             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                | 09/04/2024   | n/a        |                 |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------|
| IA/0041             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                            | 04/05/2023   | 22/05/2024 | Annex II and PL |                                   |
| PSUSA/10585 /202208 | Periodic Safety Update EU Single assessment - budesonide / formoterol                                                                                                                                                                                                                       | 14/04/2023   | n/a        |                 | PRAC Recommendation - maintenance |
| IG/1579             | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                                                       | 19/12/2022   | n/a        |                 |                                   |
| IG/1560             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                            | 08/12/2022   | n/a        |                 |                                   |
| IG/1510/G           | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or | 26/05/2022   | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|           | deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                                  |                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------|
| IG/1491/G | This was an application for a group of variations. B.II.d.2.f - Change in test procedure for the finished product - To reflect compliance with the Ph. Eur. and remove reference to the outdated internal test method and test method number B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of | 22/03/2022 | n/a        |                                  |                                                                                   |
| IG/1472   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                    | 14/01/2022 | n/a        |                                  |                                                                                   |
| II/0033/G | This was an application for a group of variations. Extension of Indication to include adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is                                                                                                                                                                                                                                                                                                                     | 22/04/2021 | 21/05/2021 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'DuoResp Spiromax EMEA/H/C/002348/II/0033'. |

<div style=\"page-break-after: always\"></div>

|                     | appropriate: in patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 adrenoceptor agonists; or in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. As a consequence, sections 4.1, 4.2, and 5.1 of the SmPC have been updated and the labelling and Package Leaflet have been updated accordingly. In addition, Changes were made to sections 4.4 and 4.8 of the SmPC to align information with the reference medicinal product, Symbicort Turbohaler. The MAH also took the opportunity to make administrative updates to the Greek, Islandic, Irish and Maltese local representatives phone numbers in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.2. RMP version 3.3 is considered acceptable. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |             |                                                                                                                                                     |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10585 /201908 | Periodic Safety Update EU Single assessment - budesonide / formoterol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 30/04/2020 | 13/07/2020 | SmPC        | Please refer to PSUSA-10585-201908 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. |
| IA/0034             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 29/06/2020 | n/a        |             |                                                                                                                                                     |
| II/0030             | Updates of section 4.2 to add information on the use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 30/01/2020 | 09/03/2020 | SmPC and PL | In section 4.2 of the SmPC, information related to the use                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | as reliever for allergen- and exercise-induced bronchoconstriction, section 4.4 to revise the general warning on complete withdrawal of inhaled corticosteroids; and section 6.6 to update the statement on special precautions for disposal and other handling following assessment of the same changes for the reference product Symbicort Turbohaler 160 mcg/4.5 mcg. The Package Leaflet (PL) and Labelling are updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the PL and to introduce some minor editorial amendments in the PI for the following languages: FR, NO and PT. C.I.2.b - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Change(s) require to be further substantiated by new additional data to be submitted   |            |     | of DuoResp Spiromax as reliever therapy for allergen- and exercise-induced bronchoconstriction was added to inform that preventative use of DuoResp Spiromax should be discussed between physician and patient; the recommended use should take into consideration the frequency of need. In case of frequent need of bronchodilation without corresponding need for an increased dose of inhaled corticosteroids, an alternative reliever should be used. Section 4.4 of the SmPC is updated to inform healthcare professionals that the complete withdrawal of inhaled corticosteroids should not be considered unless it is temporarily required to confirm diagnosis of asthma. Section 6.6 of the SmPC is updated to reflect that any unused medicinal product or waste material should be disposed of in accordance with local requirements. The PL is updated accordingly.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0032   | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 31/01/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0029/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 28/06/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           | starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   |            |            |                                  |                                                                                                                                                                                                                                                                                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0028    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                     | 12/06/2019 | 09/03/2020 | PL                               |                                                                                                                                                                                                                                                                                |
| R/0027    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 31/01/2019 | 08/04/2019 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of DuoResp Spiromax in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| II/0026   | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                                                                                                                                                                                                  | 08/11/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                                |
| II/0024/G | This was an application for a group of variations. B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product                                                                                                                                                                                                         | 26/07/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|           | - Change in the batch size (including batch ranges) of the finished product - The change to all other pharmaceutical forms by complex manufacturing processes                                                                                                |            |            |                        | B.II.b.4.d size relates manufactured   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------|
| IB/0025   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 10/07/2018 | 08/04/2019 | SmPC                   |                                        |
| IA/0023   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                  | 08/03/2018 | n/a        |                        |                                        |
| IAIN/0021 | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority                   | 08/06/2017 | 12/03/2018 | SmPC and PL            |                                        |
| IB/0019   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                   | 19/04/2017 | n/a        |                        |                                        |
| IB/0020/G | This was an application for a group of variations. B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information                                    | 24/03/2017 | 12/03/2018 | SmPC, Labelling and PL |                                        |

<div style=\"page-break-after: always\"></div>

|                     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |     |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0018             | B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms                                                                                                                                                                                                                  | 24/02/2017 | n/a |                                   |
| PSUSA/10202 /201604 | Periodic Safety Update EU Single assessment - budesonide / formoterol (only centrally authorised products)                                                                                                                                                                                                                                                    | 01/12/2016 | n/a | PRAC Recommendation - maintenance |
| IB/0016/G           | This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.7.z. - Change in supplier of packaging components or devices (when mentioned in the dossier) - Other variation       | 17/10/2016 | n/a |                                   |
| IAIN/0017           | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                     | 07/10/2016 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| A31/0008            | Pursuant to Article 31 of Directive 2001/83/EC, the European Commission initiated a procedure on 27 April 2015 further to concerns over the risk of pneumonia in patients with chronic obstructive pulmonary disease when treated with inhaled corticosteroids containing medicinal products. The PRAC was requested to assess the impact thereof on the benefit-risk balance of inhaled corticosteroids containing medicinal products and to give its recommendation whether the marketing authorisation of these products should be maintained, varied, suspended or revoked.   | 28/04/2016   | 04/07/2016   | SmPC and PL   | Please refer to the assessment report: Inhaled corticosteroids containing products indicated in the treatment of chronic obstructive pulmonary disease- EMEA/H/A-31/1415   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0014/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                               | 14/06/2016   | n/a          |               |                                                                                                                                                                            |
| PSUSA/10202 /201510 | Periodic Safety Update EU Single assessment - budesonide / formoterol (only centrally authorised products)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 13/05/2016   | n/a          |               | PRAC Recommendation - maintenance                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IB/0013             | B.II.e.1.z - Change in immediate packaging of the finished product - Other variation                                                                                                                                                                                                                                                                                                      | 22/04/2016   | n/a   |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10202 /201504 | Periodic Safety Update EU Single assessment - budesonide / formoterol (only centrally authorised products)                                                                                                                                                                                                                                                                                | 06/11/2015   | n/a   | PRAC Recommendation - maintenance |
| IB/0011/G           | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                     | 17/09/2015   |       | SmPC, Annex Labelling and PL      |
| IA/0009/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 24/07/2015   | n/a   |                                   |
| PSUSA/10202 /201410 | Periodic Safety Update EU Single assessment - budesonide / formoterol (only centrally authorised products)                                                                                                                                                                                                                                                                                | 07/05/2015   | n/a   | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IAIN/0007   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                | 13/03/2015   | n/a   |                      |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------------------|
| II/0002/G   | This was an application for a group of variations. additional finished product manufacturer B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 18/12/2014   | n/a   | procedure            |
| IA/0004     | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                       | 27/08/2014   | n/a   |                      |
| IAIN/0003/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - of a site where batch                                                                                                                                                                                                                   | 18/08/2014   | n/a   | Replacement/addition |

<div style=\"page-break-after: always\"></div>

|           | control/testing takes place                                                                                                                                                                                                            |            |            |                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IAIN/0001 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 21/07/2014 | 08/07/2015 | Annex II and PL |